NCT07339761

Brief Summary

Despite increasing recognition of sexual dysfunction and sexual distress as important survivorship issues in oncology, research and clinical attention remain uneven across cancer types. This imbalance is particularly evident in bladder cancer, where sexual health has received limited research and clinical attention. However, existing studies demonstrate substantial sexual dysfunction and reduced intimacy among patients following disease and treatment. The treatment of bladder cancer is a multimodal and multidisciplinary discipline. Low-risk non-muscle-invasive bladder cancer (NMIBC) is treated by transurethral resection of the bladder (TURB) alone, while recurrent intermediate- and high-risk NMIBC undergo a combination of TURB and adjuvant intravesical instillation therapy. For patients with muscle-invasive bladder cancer (MIBC) and specific high-risk NMIBC cases, the first-line treatment option is radical cystectomy with urinary diversion, with or without neoadjuvant chemotherapy. These treatment modalities are known to have a negative impact on sexual function, and studies in both men and women demonstrate profound impairments in sexual function, intimacy, and body image after treatment. Among men, erectile and ejaculatory dysfunction are prevalent for this patient group and frequently associated with diminished sexual satisfaction and body-image concerns. Likewise, women experience loss of sexual desire, orgasmic disorders, dyspareunia, and vaginal dryness following cystectomy. A targeted literature search further identified no contemporary sexology-focused interventional or feasibility trials specifically in bladder cancer (neither MIBC or NMIBC). Existing evidence on the topic is largely descriptive or addresses non-sexological rehabilitation, demonstrating a evidence gap\[1\]. Qualitative research has also explored informational and psychosocial needs among bladder cancer patients, revealing limited communication about sexual health and unmet needs for professional support. Such studies provide valuable insight into patient experiences but have not yet translated this knowledge into the development of structured, sexological interventions. Evidence from other cancer populations demonstrates that counselling and psychoeducational programmes addressing intimacy and sexuality are both feasible and beneficial, suggesting that similar interventions could be adapted for bladder cancer care. To develop a relevant and acceptable intervention, it is essential to understand how patients themselves perceive their sexual health challenges, informational needs, and preferences for professional support regarding sexual health. This project therefore consists of two sequential sub-studies:

  • Study 1a (Development phase): A qualitative, exploratory study to develop a sexological intervention with patient and clinician involvement.
  • Study 1b (Feasibility phase): A one-armed feasibility trial assessing the implementation and acceptability of the intervention among patients with muscle-invasive bladder cancer (MIBC).

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
28mo left

Started Jan 2026

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress13%
Jan 2026Aug 2028

First Submitted

Initial submission to the registry

December 10, 2025

Completed
22 days until next milestone

Study Start

First participant enrolled

January 1, 2026

Completed
13 days until next milestone

First Posted

Study publicly available on registry

January 14, 2026

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2027

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2028

Last Updated

January 14, 2026

Status Verified

October 1, 2025

Enrollment Period

1.7 years

First QC Date

December 10, 2025

Last Update Submit

January 5, 2026

Conditions

Keywords

Sexual HealthBladder CancerSexual Rehabilitation

Outcome Measures

Primary Outcomes (8)

  • Study 1a: Patient-perceived sexual health challenges identified through semi-structured qualitative interviews

    Patient perceptions of sexual health challenges will be explored through semi-structured individual interviews. Interviews will be audio-recorded, transcribed verbatim, and analyzed using thematic analysis. Results will be reported as descriptive themes representing common challenges across participants.

    1 year

  • Study 1a: Patient informational needs regarding sexual health identified through semi-structured qualitative interviews

    Patient informational needs related to sexual health will be assessed through semi-structured individual interviews. Interview transcripts will be analyzed using thematic analysis, and results will be reported as themes describing shared informational needs.

    1 year

  • Study 1a: Patient preferences for professional sexual health support identified through semi-structured qualitative interviews

    Patient preferences for professional sexual health support will be explored using semi-structured individual interviews. Data will be analyzed using thematic analysis, and findings will be reported as themes describing preferred type, timing, and format of support.

    1 year

  • Study 1b: Recruitment rate

    Recruitment rate will be defined as the number of participants enrolled divided by the number of eligible participants approached during the recruitment period.

    2 years

  • Study 1b: Retention rate

    Retention rate will be defined as the proportion of enrolled participants who complete all required study assessments.

    2 years

  • Study 1b: Adherence to study protocol

    Protocol adherence will be assessed as the proportion of participants who complete the intervention according to the predefined study procedures.

    2 years

  • Study 1b: Response rate to patient-reported outcome measures

    Response rate will be defined as the proportion of completed patient-reported outcome questionnaires out of the total number of questionnaires distributed.

    2 years

  • Study 1b: Data completeness of patient-reported outcome measures

    Data completeness will be assessed as the proportion of fully completed items across all patient-reported outcome measures.

    2 years

Secondary Outcomes (3)

  • Study 1b: Sexual function assessed by the Female Sexual Function Index (FSFI)

    2 years

  • Study 1b: Sexual distress assessed by the Female Sexual Distress Scale-Revised (FSDS-R)

    2 years

  • Study 1b: Wellbeing assessed by the WHO-5 Well-Being Index

    2 years

Study Arms (1)

Intervention arm (study 1b)

EXPERIMENTAL
Other: Sexological Support

Interventions

Results from Study 1a will inform the development and refinement of the intervention to be tested in the feasibility phase (Study 1b).

Intervention arm (study 1b)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • The participant has one of the following diagnoses and received initial treatment approximately 12 months ago:
  • Non-muscle-invasive bladder cancer treated with transurethral resection of the bladder (TUR-B)
  • Non-muscle-invasive bladder cancer treated with TUR-B and subsequent intravesical instillation therapy with chemotherapy or immunotherapy
  • Muscle-invasive bladder cancer treated with cystectomy (removal of the bladder)
  • The participant has experienced changes and/or difficulties in sexual function related to the cancer diagnosis and/or its treatment
  • The participant speaks and understands Danish
  • The participant is aged 18 years or older
  • The participant has read and understood the oral and written study information
  • The participant has provided written informed consent

You may not qualify if:

  • The participant has a history of other cancers located in the pelvic region, including rectal cancer, sarcomas, uterine cancer, cervical cancer, ovarian cancer, prostate cancer, or penile cancer
  • The participant has a history of breast cancer
  • The participant is diagnosed with Muscle-invasive bladder cancer treated with cystectomy (removal of the bladder)
  • The participant speaks and understands Danish
  • The participant is aged 18 years or older
  • The participant has read and understood the oral and written study information
  • The participant has provided written informed consent
  • The participant has a history of other cancers located in the pelvic region, including rectal cancer, sarcomas, uterine cancer, cervical cancer, ovarian cancer, prostate cancer, or penile cancer
  • The participant has a history of breast cancer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Urology, Aarhus University Hospital

Aarhus, 8200, Denmark

RECRUITING

MeSH Terms

Conditions

Urinary Bladder NeoplasmsNon-Muscle Invasive Bladder Neoplasms

Condition Hierarchy (Ancestors)

Urologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteNeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesUrinary Bladder DiseasesUrologic DiseasesMale Urogenital DiseasesCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic Type

Central Study Contacts

Charlotte Graugaard-Jensen

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SEQUENTIAL
Model Details: * Study 1a (Development phase): A qualitative, exploratory study to develop a sexological intervention with patient and clinician involvement. * Study 1b (Feasibility phase): A one-armed feasibility trial assessing the implementation and acceptability of the intervention among patients with muscle-invasive bladder cancer (MIBC).
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 10, 2025

First Posted

January 14, 2026

Study Start

January 1, 2026

Primary Completion (Estimated)

August 31, 2027

Study Completion (Estimated)

August 31, 2028

Last Updated

January 14, 2026

Record last verified: 2025-10

Locations